Martin Capital Partners’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.04M | Sell |
4,897
-25
| -0.5% | -$4.91K | 0.38% | 43 |
|
|
2026
Q1 | $965K | Buy |
4,922
+8
| +0.2% | +$1.55K | 0.36% | 42 |
|
|
2025
Q4 | $853K | Sell |
4,914
-10
| -0.2% | -$1.82K | 0.32% | 48 |
|
|
2025
Q3 | $938K | Sell |
4,924
-183
| -4% | -$32.5K | 0.36% | 41 |
|
|
2025
Q2 | $917K | Buy |
5,107
+3,371
| +194% | +$586K | 0.36% | 46 |
|
|
2025
Q1 | $294K | Buy |
1,736
+28
| +2% | +$4.6K | 0.35% | 50 |
|
|
2024
Q4 | $258K | Sell |
1,708
-2,598
| -60% | -$404K | 0.31% | 50 |
|
|
2024
Q3 | $669K | Sell |
4,306
-1,716
| -28% | -$256K | 0.33% | 50 |
|
|
2024
Q2 | $824K | Sell |
6,022
-196
| -3% | -$26.8K | 0.33% | 48 |
|
|
2024
Q1 | $828K | Sell |
6,218
-47
| -0.8% | -$6.1K | 0.32% | 50 |
|
|
2023
Q4 | $864K | Sell |
6,265
-26
| -0.4% | -$3.42K | 0.35% | 49 |
|
|
2023
Q3 | $767K | Buy |
6,291
+48
| +0.8% | +$6.39K | 0.32% | 52 |
|
|
2023
Q2 | $878K | Buy |
6,243
+121
| +2% | +$16.7K | 0.36% | 48 |
|
|
2023
Q1 | $866K | Buy |
6,122
+212
| +4% | +$30.3K | 0.36% | 44 |
|
|
2022
Q4 | $925K | Buy |
5,910
+316
| +6% | +$45.4K | 0.38% | 44 |
|
|
2022
Q3 | $686K | Buy |
5,594
+828
| +17% | +$109K | 0.32% | 51 |
|
|
2022
Q2 | $634K | Buy |
4,766
+34
| +0.7% | +$4.63K | 0.3% | 49 |
|
|
2022
Q1 | $648K | Buy |
4,732
+13
| +0.3% | +$1.81K | 0.3% | 50 |
|
|
2021
Q4 | $816K | Buy |
4,719
+93
| +2% | +$14.2K | 0.39% | 44 |
|
|
2021
Q3 | $672K | Sell |
4,626
-20
| -0.4% | -$2.93K | 0.34% | 44 |
|
|
2021
Q2 | $613K | Buy |
4,646
+256
| +6% | +$33.5K | 0.31% | 46 |
|
|
2021
Q1 | $563K | Buy |
4,390
+642
| +17% | +$79.1K | 0.3% | 48 |
|
|
2020
Q4 | $447K | Buy |
3,748
+157
| +4% | +$19.1K | 0.26% | 50 |
|
|
2020
Q3 | $411K | Buy |
3,591
+10
| +0.3% | +$1.18K | 0.27% | 43 |
|
|
2020
Q2 | $408K | Buy |
3,581
+666
| +23% | +$70.6K | 0.29% | 42 |
|
|
2020
Q1 | $234K | Sell |
2,915
-54
| -2% | -$5.59K | 0.18% | 49 |
|
|
2019
Q4 | $317K | Buy |
2,969
+942
| +46% | +$98.2K | 0.19% | 49 |
|
|
2019
Q3 | $217K | Buy |
2,027
+13
| +0.6% | +$1.33K | 0.15% | 49 |
|
|
2019
Q2 | $205K | Sell |
2,014
-115
| -5% | -$11.1K | 0.15% | 48 |
|
|
2019
Q1 | $191K | Buy |
+2,129
| New | +$184K | 0.15% | 52 |
|
|
2018
Q4 | – | Sell |
-2,204
| Closed | -$238K | – | 53 |
|
|
2018
Q3 | $238K | Buy |
+2,204
| New | +$242K | 0.21% | 52 |
|
Other funds holding DGX
EIG
Martin Capital Partners's DGX Position: Q2 2026 in Review
Martin Capital Partners reduced its Quest Diagnostics (DGX) stake by 0.51% in Q2 2026, selling an estimated $4.91K and leaving 4,897 shares worth $1.04M. The position accounts for 0.38% of the portfolio, ranked #43.
Martin Capital Partners first reported a position in DGX in Q3 2018 and has held it in 31 quarters since. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.
- Martin Capital Partners held 4,897 shares of Quest Diagnostics worth $1.04M as of Q2 2026.
- Martin Capital Partners sold 25 Quest Diagnostics shares in Q2 2026, an estimated $4.91K.
- Quest Diagnostics made up 0.38% of Martin Capital Partners's portfolio in Q2 2026, its #43 holding.
- Martin Capital Partners first reported a position in Quest Diagnostics in Q3 2018 and has held it in 31 quarters since.
- 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.
Based on Martin Capital Partners's 13F filing for Q2 2026, filed 7 Jul 2026.